KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Gross Margin: 2014-2025

Historic Gross Margin for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to 88.87%.

  • Aurinia Pharmaceuticals' Gross Margin fell 223.00% to 88.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.93%, marking a year-over-year increase of 168.00%. This contributed to the annual value of 87.99% for FY2024, which is 395.00% down from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Gross Margin of 88.87% as of Q3 2025, which was down 1.08% from 89.84% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Gross Margin's 5-year high stood at 98.82% during Q1 2022, with a 5-year trough of 84.42% in Q2 2024.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Gross Margin value was 88.87% (recorded in 2025), while the average stood at 89.68%.
  • In the last 5 years, Aurinia Pharmaceuticals' Gross Margin plummeted by 1,419bps in 2024 and then surged by 541bps in 2025.
  • Aurinia Pharmaceuticals' Gross Margin (Quarterly) stood at 97.94% in 2021, then plummeted by 273bps to 95.21% in 2022, then crashed by 717bps to 88.04% in 2023, then skyrocketed by 269bps to 90.73% in 2024, then tumbled by 223bps to 88.87% in 2025.
  • Its Gross Margin stands at 88.87% for Q3 2025, versus 89.84% for Q2 2025 and 86.27% for Q1 2025.